These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38085681)

  • 1. Single Site
    Huang HW; Chen CC; Lin KI; Hsu TL; Wong CH
    ACS Chem Biol; 2024 Jan; 19(1):153-161. PubMed ID: 38085681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. γ-Secretase directly sheds the survival receptor BCMA from plasma cells.
    Laurent SA; Hoffmann FS; Kuhn PH; Cheng Q; Chu Y; Schmidt-Supprian M; Hauck SM; Schuh E; Krumbholz M; Rübsamen H; Wanngren J; Khademi M; Olsson T; Alexander T; Hiepe F; Pfister HW; Weber F; Jenne D; Wekerle H; Hohlfeld R; Lichtenthaler SF; Meinl E
    Nat Commun; 2015 Jun; 6():7333. PubMed ID: 26065893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention.
    Huang HW; Chen CH; Lin CH; Wong CH; Lin KI
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):10928-33. PubMed ID: 23776238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic defects of gamma-secretase genes in a multiple myeloma patient with high and dysregulated BCMA surface density: A case report.
    Cattaneo I; Valgardsdottir R; Cavagna R; Spinelli O; Bartoletti-Stella A; Capellari S; Galli M; Golay J
    Br J Haematol; 2024 Feb; 204(2):571-575. PubMed ID: 37957838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unveiling the link between genetic alterations in gamma secretase and BCMA surface density in multiple myeloma.
    Cowan AJ; Green DJ
    Br J Haematol; 2024 Feb; 204(2):391-392. PubMed ID: 38014717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
    Pont MJ; Hill T; Cole GO; Abbott JJ; Kelliher J; Salter AI; Hudecek M; Comstock ML; Rajan A; Patel BKR; Voutsinas JM; Wu Q; Liu L; Cowan AJ; Wood BL; Green DJ; Riddell SR
    Blood; 2019 Nov; 134(19):1585-1597. PubMed ID: 31558469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
    Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
    Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.
    Li D; Que Y; Ding S; Hu G; Wang W; Mao X; Wang Y; Li C; Huang L; Zhou J; Zhang W; Xiao M
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36137648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.
    García-Guerrero E; Rodríguez-Lobato LG; Sierro-Martínez B; Danhof S; Bates S; Frenz S; Haertle L; Götz R; Sauer M; Rasche L; Kortüm KM; Pérez-Simón JA; Einsele H; Hudecek M; Prommersberger SR
    Haematologica; 2023 Feb; 108(2):568-580. PubMed ID: 36722406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
    Meinl E; Krumbholz M
    Curr Opin Immunol; 2021 Aug; 71():117-123. PubMed ID: 34330018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
    Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
    Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.
    Lee L; Draper B; Chaplin N; Philip B; Chin M; Galas-Filipowicz D; Onuoha S; Thomas S; Baldan V; Bughda R; Maciocia P; Kokalaki E; Neves MP; Patel D; Rodriguez-Justo M; Francis J; Yong K; Pule M
    Blood; 2018 Feb; 131(7):746-758. PubMed ID: 29284597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways.
    Shen X; Guo Y; Qi J; Shi W; Wu X; Ju S
    Cell Biochem Funct; 2016 Mar; 34(2):104-10. PubMed ID: 26914861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF.
    He C; Zhang M; Liu L; Han Y; Xu Z; Xiong Y; Yan F; Su D; Chen H; Zheng Y; Cheng F
    Acta Biomater; 2022 Apr; 143():406-417. PubMed ID: 35218967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel BCMA Immunohistochemistry Assay Reveals a Heterogenous and Dynamic BCMA Expression Profile in Multiple Myeloma.
    Zhang M; Gray F; Cushman I; Wurmser A; Chan H; Couto S; Wang M; Nakayama Y; Hagner P; Al-Masri H; Williams S; Hersey S
    Mod Pathol; 2023 Apr; 36(4):100050. PubMed ID: 36788077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
    Chen H; Li M; Xu N; Ng N; Sanchez E; Soof CM; Patil S; Udd K; Bujarski S; Cao J; Hekmati T; Ghermezi M; Zhou M; Wang EY; Tanenbaum EJ; Zahab B; Schlossberg R; Yashar MA; Wang CS; Tang GY; Spektor TM; Berenson JR
    Leuk Res; 2019 Jun; 81():62-66. PubMed ID: 31035033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase.
    Hatzoglou A; Roussel J; Bourgeade MF; Rogier E; Madry C; Inoue J; Devergne O; Tsapis A
    J Immunol; 2000 Aug; 165(3):1322-30. PubMed ID: 10903733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.